https://www.prnewswire.com/news-releases/servier-and-taiho-oncology-present-overall-survival-data-for-trifluridinetipiracil-lonsurf-in-combination-with-bevacizumab-in-patients-with-refractory-metastatic-colorectal-cancer-at-2023-asco-gastrointestinal-cancers-symposiu-301723662.html
0
0
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium - PR Newswire
1/17/23 at 10:00pm
Organization
PRNewswire
Authors
Details
54 words
Summarize
Cancer Business & Industrial Pharmaceuticals & Biotech Taiho Oncology Present Overall Survival Data Servier Tipiracil Trifluridine LONSURF ASCO Gastrointestinal Cancers Symposium Patients With Refractory Metastatic Colorectal Cancer PRNewswire Taiho Oncology, Inc.
/PRNewswire/ -- Servier and Taiho Oncology, Inc., today announced the release of data from SUNLIGHT, a pivotal Phase 3 global trial evaluating the combination...
Create an account or login to join the discussion